

# Weill Medical College of Cornell University

Date of preparation: January 27, 2009

## A. GENERAL INFORMATION

1. Name: Neil H Bander
2. Office address, telephone, fax:  
  
Laboratory of Urological Oncology  
  
Weill Medical College of Cornell University  
  
1300 York Avenue, E-300  
  
New York, New York 10021
3. Beeper: -- none
4. Email: nhbander@med.cornell.edu

5 Languages spoken/written: English

6. Gender: Male

## B. EDUCATIONAL BACKGROUND

1. Degree(s)(B.A. and above), institution name and location, dates attended, and date(s) of award (*in chronological order beginning with B.A. or equivalent*)

Degree	Institution name and location	Dates attended	Year awarded
B.A.	Johns Hopkins University Baltimore, Maryland	1965-1969	1969
M.D.	Univ of Connecticut Medical School Farmington, Connecticut	1969-1974	1974

## C. PROFESSIONAL POSITIONS AND EMPLOYMENT

*(In chronological order beginning with post-doctoral training positions; include full titles, ranks and inclusive dates held)*

1. Post-doctoral training (include residency/fellowships)

Title	Institution name and location	Dates held
Intern	New York University – Bellevue Medical Center	1974-75
Junior Resident	New York University – Bellevue Medical Center	1975- 76
Resident, Gen Surgery	New York University – Bellevue Medical Center	1976-77
Resident, Urology	Univ of Connecticut Medical Center	1977–78
Senior Resident, Urology	Univ Connecticut Medical Center	1978-79
Chief Resident, Urology	Univ of Connecticut Medical Center	1979-80
Research Fellow, Immunology	Sloan-Kettering Inst for Cancer Research	1980-83
Fellow, Urologic Oncology	Memorial Hospital	1982-83

## 2. Academic positions (teaching and research)

Title	Institution name and location	Dates held
Assist – Assoc Professor of Urology, Weill Medical College of Cornell University		1983 -1998
Professor of Urology, Weill Medical College of Cornell University;		1998 - present
Incumbent, Bernard and Josephine Chaus Chair in Urologic Oncology;		1991 - present
Director, Urological Oncology Research Program		1990 - present
Member (Affiliate), Memorial Sloan-Kettering Cancer Center		2000 - present
Assist Member, Ludwig Institute for Cancer Research, MSKCC		1992 - 1999

## Hospital positions (e.g., attending physician)

Title	Institution name and location	Dates held
Attending Surgeon	Department of Urology New York Presbyterian Hospital, New York NY	1998 -present



Member	American Association for Cancer Research	1990 - present
Member	American Association of Clinical Urologists, Inc	1998 - present
Member	Medical Advisory Board, National Kidney Cancer Assoc	1985 - 2005
Member	New York Section, American Urological Association	1985 - present
Member	Society of Urologic Oncology	1987 - present

**F. HONORS AND AWARDS (in chronological order)**

1.	Name of award awarded	Date
	American Cancer Society Pre-doctoral Research Fellowship, Dana-Farber Cancer Center/Harvard Medical School (Mentor: Sidney Farber, M.D.)	1969-70
	Mosby Scholarship Award, University of Connecticut Medical School	1973-74
	National Institutes of Health Immunobiology Fellowship, Memorial Sloan-Kettering Cancer Center (Mentor: Lloyd J. Old, M.D.)	1980-83
	New York Academy of Medicine, Ferdinand C. valentine Fellow in Urology (Mentor: Willet F. Whitmore, Jr., M.D., Memorial Sloan-Kettering Cancer Center	1982-83
	Society of Surgical Oncology Ewing Research Award	1983
	Deutsche Gesellschaft fur Urologie (German Urological Association) Prize for Experimental Research	1989
	Visiting Lecturer, Japanese Urological Association	1992
	Assoc for the Cure of Prostate Cancer (CaP Cure) Award (for each year)	1993-2002
	Visiting Professor, Roswell Park Cancer Institute	2005
	Visiting Professor, VIth European Symposium of the Protein Society	2005
	Visiting Professor, MIT, Langer Lab Seminar Series	2006
	Visiting Professor, The Cancer Institute of New Jersey	2008

**G. INSTITUTIONAL/HOSPITAL AFFILIATION**

1. Primary Hospital Affiliation: **New York Presbyterian Hospital**
2. Other Hospital Affiliations
3. Other Institutional Affiliations

**H. EMPLOYMENT STATUS**

1. Name of Current Employer(s):

2. Employment Status (*choose one*):
- Full-time salaried by Cornell **Yes**
  - Full-time salaried at Cornell-affiliated hospital
  - Part-time salaried at Cornell
  - Part-time salaried at Cornell-affiliated hospital
  - Voluntary (self-employed or member of a P.C.)
  - Other salaried
  - Other non-salaried

**I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT** (*in chronological order; specify below whether an activity involves WMC and/or MSK students/researchers*)

- Teaching/Mentoring (e.g., specific teaching and mentoring activities, courses taught, dates)
- Clinical care (duties, dates)
- Administrative duties, including committees, dates
- Research

	<u>Current Percent Effort (%)</u>	<u>Does the activity involve WMC students or researchers? (Y/N)</u>	<u>Does the activity involve MSK trainees or researchers? (Y/N)</u>
Teaching/Mentoring	15%	Yes	Yes
Clinical Care	0	N	N
Administration	5%	N	N
Research	80%	N	N
<b>TOTAL:</b>	<b>100%</b>		

**J. RESEARCH SUPPORT**

*(Summarize [in chronological order] past research support and list the following for current extramural and intramural research funding)*

**Individual's role in project, including percent (%) effort**

Department of Defense Grant #W81XWH-04-0884 – 2004 – 2009,

Neil H Bander, Co-PI Radioimmunotherapy (RIT) Dose Escalation studies in Prostate Cancer Using Anti-PSMA Antibody 177Lu-J591: RIT Alone and RIT in Combination with Docetaxel.

Department of Defense Grant #W81XWH-06-1-0229 – 2006 –2009,

Neil H Bander, Co-PI Investigating the Functional Role of Prostate-Specific Membrane Antigen and its Enzymatic Activity in Prostate Cancer Metastasis

CaP CURE Foundation – 1993-2002

Neil H Bander, PI

Cancer Research Institute – 1999-2008

Neil H Bander, PI

Prostate Cancer Therapy with Monoclonal Antibody to Prostate Specific Membrane Antigen

David Koch Foundation – 1995-2011  
Neil H Bander, PI  
Prostate Cancer Therapy with Monoclonal Antibody to Prostate Specific Membrane Antigen

Peter Sacerdote Foundation – 2001-2005  
Neil H Bander, PI  
Prostate Cancer Therapy with Monoclonal Antibody to Prostate Specific Membrane Antigen

Harvard-MIT-Cornell Consortium: Development of Targeted Nano-Particles for Prostate Cancer Therapy – 2007 - 2011  
Neil H Bander, Co-PI Program to develop PSMA-targeted drug-containing nano-particles for therapy of Prostate Cancer

Bernard & Josephine Chaus Chair in Urologic Oncology – 1988-present

**K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES**

*(e.g., Invited lectures, Journal reviewer, NIH study section, etc.)*

Editorial Board, The Prostate

Grant Review Committee, Prostate Cancer Foundation

Independent Data Safety Monitoring Committee, Dendreon, Inc.

Scientific Advisory Board, BZL Biologics, Inc

Medical Advisory Board, Agensys, Inc.

Medical Advisory Board, Centocor

Medical Advisory Board, National Kidney Cancer Fdn

Medical Advisor, Prostate Cancer Foundation (CaP CURE) 2005 Annual

Competitive Awards Program

Ad Hoc Reviewer, US Army Medical Research and Material Command, Prostate Cancer Research Program – Integration Panel

Advisory Board, Bristol-Myers Squibb, Prostate Cancer Advisory Board

Advisory Board, BIND

## L. BIBLIOGRAPHY

Entries should follow standard journal format, listing all authors, complete titles and inclusive pagination. Number the entries and put your name in bold type. The listings must be organized in chronological order within the following categories:

1. Conroy MC, **Bander NH** and Lepow IH: Effect of intradermal injections in the rat of purified proteases from *Streptococcus* and *Serratia marescens*. *Proc Soc Exp Biol Med* 1975; **150**:801-805.
2. **Bander NH**: Comparison of antigen expression of human renal cancer *in vivo* and *in vitro*. *Cancer* 1984; **53**:1235-1239.
3. Cordon-Cardo C, **Bander NH**, Fradet Y, Finstad CL, Whitmore WF Jr, Lloyd KO, Oettgen HF, Melamed MR and Old LJ: Immunoanatomic dissection of the human urinary tract by monoclonal antibodies. *J Histochem Cytochem* 1984; **32**:1035-1040.
4. **Bander NH**, Welt S, Houghton AN, Lloyd KO, Grando R, Yeh S, Whitmore WF Jr, Vaughan ED Jr, Oettgen HF and Old LJ: Radionuclide imaging of human renal cancer with labeled monoclonal antibodies. *Surg Forum* 1984; **35**:652-655.
5. **Bander NH**: Renal cancer: A model system for the study of human neoplasia. *In: Contributions in Oncology*, Riethmuller G, Koprowski H, von Kleist S, (eds). S. Karger, Basel) 1984.
6. Finstad CL, Cordon-Cardo C, **Bander NH**, Whitmore WF Jr, Melamed MR and Old LJ: Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. *Proc Natl Acad Sci USA* 1985; **82**:2955-2959.
7. **Bander NH**, Cordon-Cardo C, Finstad CL, Whitmore WF Jr, Vaughan ED Jr, Oettgen HF, Melamed MR and Old, LJ: Immunohistologic dissection of the human kidney using monoclonal antibodies. *J Urol* 1985; **133**:502-505.
8. **Bander NH**: Study of the normal human kidney and kidney cancer with monoclonal antibodies. *Uremia Invest* 1985; **8**:263-273.
9. Fleischmann J, Heston W, Bauer W, Ratliff T, **Bander NH** and Fair W: Human renal cell carcinoma xenograft morphology, growth and chemosensitivities. *J Urol* 1985; **134**:570-574.
10. Tolkoff-Rubin NE, Cosimi AB, Delmonico FL, Russell PS, Thompson RE, Piper DJ, Hansen WP, **Bander NH**, Finstad CL, Cordon-Cardo C, Klotz LH, Old and Rubin RH: Diagnosis of tubular injury in renal transplant patients by a urinary assay for a proximal tubular antigen, the adenosine-deaminase-binding protein. *Transplantation* 1986; **41**:593-597.

11. Cordon-Cardo C, Lloyd KO, Finstad CL, McGroarty ME, Reuter VE, **Bander NH**, Old LJ and Melamed MR: Immunoanatomic distribution of blood group antigens in the human urinary tract. Influence of secretor status. *Lab Invest* 1986; **55**:444-454.
12. Sternberg CN, Yagoda A, **Bander NH**, Whitmore WF Jr, Huffman JL, Fleisher M, Melamed MR, Fanucchi MP, Hollander P and Vaughan ED Jr: Phase I/II trial of intravesical methotrexate for superficial bladder tumors. *Cancer Chemother Pharmacol* 1986; **18**:265-269.
13. Tolkoff-Rubin NE, Cosimi AB, Delmonico FL, Russell PS, Thompson RE, Piper DJ, Hansen WP, **Bander NH**, Finstad CL, Cordon-Cardo C, Klotz LH, Old LJ and Rubin RH: Monitoring of renal proximal tubular injury in transplantation with a monoclonal antibody-based assay for the adenosine deaminase-binding protein. *Transplant Proc* 1986; **18**:716-718.
14. Cordon-Cardo C, Finstad CL, **Bander NH**, Old LJ and Melamed MR: Immunoanatomic distribution of cytostructural and tissue-associated antigens in the human urinary tract. *Am J Pathol* 1987; **126**:269-284.
15. Tolkoff-Rubin NE, Thompson RE, Piper DJ, Hansen WP, **Bander NH**, Cordon-Cardo C, Finstad CL, Klotz LH, Old LJ and Rubin RH: Diagnosis of renal proximal tubular injury by urinary immunoassay for a proximal tubular antigen, the adenosine deaminase-binding protein. *Nephrol Dialysis Transplant* 1987; **2**:143-148.
16. Kantor RRS, **Bander NH**, Finstad CL, Graf LH Jr, Lloyd KO, Old LJ and Albino AP: DNA-mediated gene transfer of a human cell surface 170-kilodalton glycoprotein. Evidence for association with an endogenous murine protein. *J Biol Chem* 1987; **262**:15166-15171.
17. Carter HB, Amberson JB, **Bander NH**, Badalment R, Gorelick J, Vaughan ED Jr and Whitmore WF Jr: Newer diagnostic techniques for bladder cancer. *Urol Clin N Amer* 1987; **14(4)**: 763-769.
18. **Bander NH**: Monoclonal antibodies: State of the art. *J Urol* 1987; **137**: 603-612.
19. Weir EC, Insogna KL, Brownstein DG, **Bander NH** and Broadus AE: In vitro adenylate cyclase-stimulating activity predicts the occurrence of humoral hypercalcemia of malignancy in nude mice. *J Clin Invest* 1988; **81(3)**: 818-821.
20. **Bander NH**: Continent urinary diversion in the treatment of bladder cancer. *New Developments in Medicine* 1988; **2**: 65-81.
21. Mangin M, Webb AC, Dreyer BE, Posillico JT, Ikeda K, Weir EC, Stewart AF, **Bander NH**, Barton DE, Francke U and Broadus AE: Identification of a complementary DNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. *Proc Natl Acad Sci USA* 1988; **85**: 597-601.

22. Sternberg C, Yagoda A, Scher H, Watson R, Herr H, Morse M, Sogani P, Vaughan ED Jr, **Bander NH**, Weiselberg L, Geller N, Hollander P, Lipperman R, Fair WR and Whitmore WF Jr: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. *J Urol* 1988; **139**: 461-469.
23. Ikeda K, Mangin M, Dreyer B, Webb A, Posillico J, Stewart A, **Bander NH**, Weir E, Insogna K and Broadus AE: Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNAs from a variety of human and animal tumors associated with humoral hypercalcemia of malignancy. *J Clin Invest* 1988; **81**: 2010-2014.
24. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, **Bander NH**, Geller N, Fair WR and Whitmore WF Jr: Chemotherapeutic management of invasive bladder carcinoma. *Eur Urol* 1988; **14** (suppl): 19-20.
25. **Bander NH**, Finstad CL, Cordon-Cardo C, Ramsawak RD, Vaughan ED Jr, Whitmore WF Jr, Oettgen HF, Melamed MR and Old LJ: Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets of renal cell carcinomas. *Cancer Res* 1989; **49**: 6774-6780.
26. Sternberg C, Yagoda A, Scher HI, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, **Bander NH** et al.: M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. *Cancer* 1989; **64**: 2448-2458.
27. Nanus DM, Ebrahaim SAD, **Bander NH**, Real FX, Pfeffer LM, Shapiro JR and Albino AP: Transformation of human kidney proximal tubule cells by *ras*-containing retroviruses. Implications for tumor progression. *J Exp Med* 1989; **169**: 953-972.
28. Wang JCL, Walle A, Novogrodsky A, Suthanthiran M, Silver RT, **Bander NH**, Rubin AL and Stenzel KH: A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion of interleukin-2. *J Clin Oncol* 1989; **7**: 1885-1891.
29. Yagoda A and **Bander NH**: Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. *Urol Int* 1989; **44**: 338-345.
30. Ebert T and **Bander NH**: Kidney-derived cell lines. *Seminars in Urology* 1989; **7**:247-251.
31. **Bander NH**: Monoclonal antibodies to renal cancer antigens. *Seminars in Urology* 1989; **7**: 264-270.
32. **Bander NH**: Ureteral stent for nonrefluxing, continent urinary diversions reduces complications and hospitalization for patients. *Urol* 1990; **35**: 64-67.
33. Nanus DM, Mentle IR, Motzer RJ, **Bander NH** and Albino AP: Infrequent *ras* oncogene point mutations in renal cell carcinoma. *J Urol* 1990; **143**: 175-178.

34. Nanus DM, Pfeffer LM, **Bander NH**, Bahri S and Albino AP: Anti-proliferative and anti-tumor effect of alpha-interferon in renal carcinoma: correlation to the expression of kidney associated differentiation glycoprotein. *Cancer Res* 1990; **50**: 4190-4194.
35. Ebert T, **Bander NH**, Finstad CL, Ramsawak RD and Old LJ: Establishment and characterization of renal cancer and normal kidney cell lines. *Cancer Res* 1990; **50**: 5531-5536.
36. Rettig WJ, Triche TJ and **Bander NH**: Somatic cell genetic analysis of human cell surface antigens 5.1H11 and F35/9 (gp45). *Genomics* 1990; **6**: 178-183.
37. Libby DM, **Bander NH**, Altorki NK, Gold J, Pitts WR Jr and Frankel SS: Simultaneous pulmonary and renal malignancy. *Chest* 1990; **98**: 153-156.
38. Kerr L, Huntcoon C, Donohue J, Leibson PJ, **Bander NH**, Ghose T, Luner SJ, Vessella R and McKean DJ: Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells in *in vitro* activated lymphocytes. *J Immunol* 1990; **44**: 4060-4067.
39. **Bander NH**: Monoclonal antibodies to renal cancer antigens. *Eur Urol* 1990; **18**: 10-12.
40. Ebert T, Ackerman R and **Bander NH**: Biologische marker beim nierenzellkarzinom. *Urologie* 1990; **29**: 65-70.
41. Gulmi FA and **Bander NH**: Managing carcinoma in situ of the bladder. *Contemp Urol* 1990; **1**: 45-52.
42. **Bander NH**: Initial results with a slightly modified Koch pouch. *Urol* 1991; **37**:100-105.
43. Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, **Bander NH** and Gansbacher B: Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. *Cancer Res* 1992; **52**: 6229-6236.
44. Oosterwijk E, **Bander NH**, Divgi CR, Welt S, Wakka JC, Finn R, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Oettgen HF and Old LJ: Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. *J Clin Oncol* 1993; **11**: 738-750.
45. Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, **Bander NH** and Rubin SC: High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. *Brit J Haematol* 1993; **83**: 433-441.
46. Gastl G, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, Chen N, Albino AP and **Bander NH**: Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. *Int J Cancer* 1993; **55**: 96-101.
47. Nanus DM, Engelstein D, Gastl GA, Gluck L, Vidal MJ, Morrison M, Finstad CL, **Bander NH** and Albino AP: Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A. *Proc Natl Acad Sci USA* 1993; **90**: 7069-7073.

48. Holt EH, Vasavada RC, **Bander NH**, Broadus AE and Philbrick WM: Region-specific methylation of the parathyroid hormone-related peptide gene determines its expression in human renal carcinoma cell lines. *J Biol Chem* 1993; **268**: 20639-20645.
49. Gnarr JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh F-M, Lubensky I, Duan D-S R, Florence C, Pozzatti R, Walther MM, **Bander NH** et al.: VHL tumor suppressor gene mutations in renal cell carcinoma tumorigenesis. *Nature Genet* 1994; **7**: 85-90.
50. Kinouchi T, **Bander NH** and Kotake T: Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement-dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity. *J Urol* 1995; **154**: 288-292.
51. Aoyagi T, **Bander NH**: Cytotoxicity of gallium nitrate *in vitro* using bladder cancer cells. *Int J Urol* 1995; **2(5)**: 288-294.
52. Gastl G, Ebert T, Finstad CL, Sheinfeld J, Gomahr A, Aulitzky W and **Bander NH**: MHC Class I and Class II expression in renal cell carcinoma and modulation by interferon-gamma. *J Urol* 1996; **155**: 361-367.
53. Motzer RJ, **Bander NH** and Nanus DM: Renal cell carcinoma. *N Engl J Med* 1996; **335**: 865-875.
54. McKiernan JM, Buttyan R, **Bander NH**, Stifelman MD, Katz AE, Chen M-W, Olsson CA and Sawczuk IS: Expression of the tumor-associated gene MN; a potential biomarker for human renal cell carcinoma. *Cancer Res* 1997; **57**: 2362-2365.
55. Schmetter BS, Habicht KK, Lamm DL, Morales A, **Bander NH**, Grossman HB, Hanna Jr MG, Silberman SR and Butman BT: A multicenter trial evaluation of the Aura-Tek FDP test for detection and monitoring of bladder cancer. *J Urol* 1997; **158**: 801-805.
56. Motzer RJ, **Bander NH** and Nanus DM: Letter to the Editor. *N Engl J Med* 1997; **336**: 810-811.
57. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B and **Bander NH**: Monoclonal antibodies to the extracellular domain of prostate specific membrane antigen also react with tumor vascular endothelium. *Cancer Res* 1997; **57**: 3629-3634.
58. **Bander NH**, Yao D, Liu H, Chen Y-T, Steiner M, Zuccaro W and Moy P: MHC Class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. *The Prostate* 1997; **33**: 233-239.
59. Oosterwijk E, **Bander NH**, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Oettgen HF, and Old LJ: Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. *Classic Papers and Current Comments* 1997; **2**: 331-344.

60. **Bander NH**, Cordon-Cardo C, Finstad CL, Whitmore WF Jr., Vaughan ED Jr., Oettgen HF, Melamed M, and Old LJ: Summary of Immunohistologic Dissection of the Human Kidney Using Monoclonal Antibodies. *Seminars in Urol Oncol* 1997; **15**(2): 123-130.
61. Nanus DM, Bogenrieder T, Papandreou CN, Finstad CL, Lee A, Vlamis V, Motzer RJ, **Bander NH**, Albino AP, and Reuter VE: Aminopeptidase A expression and enzymatic activity in primary human renal cancers. *Int J Oncology* 1998; **13**(2): 261-267.
62. Liu H, Rajasekaran A.K., Moy P., Xia Y., Kim S., Navarro V., Rahmati R., and **Bander NH**: Constitutive and Antibody-Induced Internalization of Prostate Specific Membrane Antigen. *Cancer Res* 1998; **58**: 4055-4060.
63. Divgi C.R., **Bander NH**, Scott A.M., O'Donoghue, Sgouros G, Welt S., Finn R.D., Morrissey F., Capitelli P., Williams J.M., Deland D., Nakhre A., Oosterwijk E., Gulec S., Graham M.C., Larson S.M., Old L.J.: Phase I/II radioimmunotherapy trial with iodine-131 labeled monoclonal antibody (mAb) G250 in metastatic renal carcinoma. *Clin Cancer Res* 1998;**4**: 2729-2739 .
64. Prewett M, Rothman M, Waksal H, Feldman M, **Bander NH**, and Hicklin D.J.: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. *Clin Cancer Res* 1998; **4**: 2957-2966.
65. Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, Molto L, Tannenbaum C, Worford LJ, Bukowski R, Tubbs R, Hsi ED, **Bander, NH**, Novick AC, and Finke JH: Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. *Clin Cancer Res* 1999; **5**: 1219-1229.
66. Kolenko V, Uzzo RG, Bukowski R, **Bander NH**, Novick AC, Finke JH: Dead or dying: Necrosis vs. apoptosis in caspase deficient human renal cell carcinoma. *Cancer Res*, 1999,**59**: 2838-2842.
67. Chang SS, Reuter VE, Heston WDW, **Bander NH**, Grauer LS, and Gaudin PB: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. *Cancer Res* 1999; **59**: 3192-3198.
68. Gong MC, Latouche JB, Krause A, Heston WDW, **Bander NH** & Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. *Neoplasia* 1999; **1**(2): 123-127 .
69. Rajasekaran SA, Ball WJ Jr, **Bander NH.**, Liu H, Pardee JD, and Rajasekaren AK: Reduced expression of  $\beta$ -subunit of Na,K-ATPase in human clear-cell renal cell carcinoma. *J Urology*, 1999; **162**: 574-580.

70. Shirakawa T, Gardner TA, Ko S-C, **Bander N**, Woo S, Gotoh A, Kamidono S, Chung LWK and Kao C: Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. *J Urology* 1999; **162**: 949-954.
71. Scanlan MJ, Gordan JD, Williamson B, Stockert E, **Bander NH**, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT and Old LJ: Antigens recognized by autologous antibody in patients with renal-cell carcinoma. *Int J Cancer* 1999, **83(4)**: 456-464.
72. Chang SS, Bander NH, Heston WDW: Monoclonal Antibodies: Will they become an integral part of the evaluation and treatment of prostate cancer-focus on prostate-specific membrane antigen. *Current Opinion In Urology* 1999; **9**: 391-395.
73. Gong MC, Chang SS, Sadelain M, **Bander NH**, Heston WDW: Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate cancer. *Cancer Metastasis Rev* 1999; **18**: 483-90.
74. McKiernan JM, Buttyan R, **Bander NH**, de la Taille A, Stifelman MD, Emanuel ER, Bagiella E, Rubin MA, Katz AE, Olsson CA, Sawczuk IS: The detection of renal cancer cells in the peripheral blood via an enhanced RT-PCR assay for MN/CA9. *Cancer*, 1999; **86(3)**: 492-497.
75. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D and **Bander NH**: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. *Cancer Res*, 2000; **60(18)**: 5237-5243.
76. McDevitt MR, Barendswaard E, Ma D, Curcio MJ, Lai L, Sgouros G, Ballangrud AM, Yang W-H, Finn RD, Geerlings MW Jr, Brechbiel MW, **Bander NH**, and Scheinberg DA: An Alpha-particle emitting antibody ([<sup>213</sup>Bi]J591) for radioimmunology of prostate cancer. *Cancer Res*. 2000; **60**: 6095-6100.
77. Gong MC, Chang SS, Watt F, O'Keefe DS, Bacich DJ, Uchida A, **Bander NH**, Reuter VE, Gaudin PB, Molloy PL, Sadelain M, Heston WD: Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. *Mol Urol* 2000 ;**4(3)**: 217-222.
78. de la Taille A; Cao Y, Sawczuk IS, Nozemu T, d'Agati V, McKiernan JM, Bagiella E, Buttyan R, Burchardt M, Olsson CA, **Bander N**, Katz AE: Detection of prostate-specific membrane antigen expressing cells in blood obtained from renal cancer patients: a potential biomarker of vascular invasion. *Cancer Detect Prev*) 2000, **24(6)**: 2008-2014.
79. Rajasekaran SA, Palmer LG, Ball WJ Jr, **Bander NH**, Alejandro Peralta Soler and Rajasekaran AK: Na,K-ATPase  $\beta$ -subunit is required for epithelial polarization, suppression of invasion and cell motility. *Mol Biol Cell* 2001; **12**: 279-295.

80. Ballangrud AM, Yang W-H, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D, **Bander NH**, Scheinberg DA and Sgouros G: Response of LNCaP spheroids after treatment with an  $\alpha$ -particle emitter ( $^{213}\text{Bi}$ )-labeled anti-prostate-specific membrane antigen antibody (J591). *Cancer Res* 2001; **61**: 2008-2014.
81. Uzzo RG, Kolenko V, Froelich CJ, Tannenbaum C, Molto L, Novick AC, **Bander NH**, Bukowski R and Finke JH: The T cell death knell: Immune-mediate tumor death in renal cell carcinoma. *Clin Cancer Res* 2001; **7**: 3276-3281.
82. Belldegrun A, **Bander NH**, Lerner SP, Wood DP, Pantuck AJ: Society of Urologic Oncology Biotechnology Forum: New Approaches and Targets for Advanced Prostate Cancer. *J Urol* 2001; **166**: 1316-1321.
83. McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank K, Wu K, Pellegrini V, Curcio MJ, Miederer M, **Bander NH**, Scheinberg, DA.: Tumor Therapy with Targeted Atomic Nano-Generators. *Science* 2001; **294**: 1537-1540.
84. Li Y, Tian Z, Rizvi S, **Bander NH**, Allen BJ: In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. *Prostate Cancer and Prostatic Dis* 2002; **5**: 36-46.
85. Smith Jones MP, Vallabhajosula S, Navarro V, Goldsmith SJ and **Bander NH**: 90Y-huJ591 mAb specific to PSMA: radioimmunotherapy (RIT) studies in nude mice with prostate cancer LNCaP tumor. *Eur J Nucl Med* 2002; **8**: 951.
86. Christiansen JJ, Rajasekaran SA, Moy P, Butch A, Goodglick, Gu Z, Reiter R, **Bander NH**, Rajasekaran AK: Polarity of prostate specific membrane antigen, prostate stem cell antigen and prostate specific antigen in prostate tissue in a cultured epithelial cell line. *The Prostate* 2003; **55**: 9-19.
87. Anilkumar G, Rajasekaran S, Wong S, Hankinson O, **Bander NH** and Rajasekaran AK: Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALAdase activity. *Cancer Res*, 2003: **63**: 2645-2648.
88. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ and **Bander NH**: Radiolabeled monoclonal antibodies specific to the extra-cellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. *J Nuc Med*, 2003; **44**: 610-617.
89. Nanus D, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ and **Bander NH**: Clinical use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen. *J Urol*, 2003;**170**: S84-S89.
90. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, **Bander NH**, Rajasekaran AK: A novel cytoplasmic tail MXXXL motif mediates the internalization and lysosomal targeting of prostate specific membrane antigen. *Molecular & Cell Biology*, 2003;**14**: 4835-4845.

91. **Bander, NH**, Trabulsi E, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM and Goldsmith SJ: Targeting Metastatic Prostate Cancer with Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen. *J Urol*, 2003; **170**: 1717-1721.
92. **Bander, NH**, Nanus, D.M., Milowsky, M.I., Kostakoglu, L., Vallabahajosula, S., and Goldsmith, S.J.: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate specific membrane antigen (PSMA). *Seminars in Oncology*, 2003; **30**: 667-676.
93. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ and **Bander NH**: Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice. *The Prostate*, 2004; **58**: 145-155.
94. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, and **Bander NH**: Phase I Trial Results of Yttrium-<sup>90</sup> Labeled Anti-Prostate Specific Membrane Antigen Monoclonal Antibody J591 in the Treatment of Patients with Recurrent Prostate Cancer. *J Clin Onc*, 2004; **22**: 2522-2531.
95. Patri AK, Myc A, Beals, J, Thomas TP, **Bander NH**, Baker JR: Synthesis and *in vitro* testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. *Bioconjug Chem*, 2004; **15**: 1174-1181.
96. Konishi S, Hamacher K, Vallabhajosula S, Kothari P, Bastidas D, **Bander NH**, Goldsmith S: Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method? *Cancer Biother Radiophar* 2004; **19**: 706-715.
97. Kelly JD, Dai J, Eschwege P, Goldbreg JS, Duggan BP, Williamson KE, **Bander NH**, Nanus DM: Downregulation of Bcl-2 sensitizes interferon-resistant renal cancer cells to Fas. *Br J Cancer* 2004; **91**: 164-170.
98. Christiansen JJ, Rajasekaran SA, Weimbs T, Gopalakrishna A, **Bander NH** and Rajasekaran AK: N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. *Mol.Bio.Cell*, 2005; **4**: 1-11.
99. **Bander NH**, Milowsky MI, Nanus DM, Kostakoglu L., Vallabhajosula S, and Goldsmith SJ: Phase I Trial Results of <sup>177</sup>Lutetium Labeled J591, A Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer. *J Clin Onc*, 2005; **23**:4591-4601.
100. Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowsky MI, Nanus DM, **Bander NH** and Goldsmith SJ: Pharmacokinetics and Biodistribution of <sup>111</sup>In and <sup>177</sup>Lu Labeled J591 Antibody Specific to Prostate Specific Membrane Antigen: Prediction of <sup>90</sup>Y-J591 Radiation Dosimetry Based on <sup>111</sup>In and <sup>177</sup>Lu. *J Nuc Med*, 2005; **46**: 634-641.

101. Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowsky MI, Nanus DM and **Bander NH**: Prediction of Myelotoxicity Based on Bone Marrow Radiation Absorbed Dose: Radioimmunotherapy Studies using  $^{90}\text{Y}$  and  $^{177}\text{Lu}$  labeled J591 Antibodies Specific to Prostate Specific Membrane Antigen (PSMA). *J Nuc Med*, 2005; **46**:850-858.
102. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM and **Bander NH**: Radioimmunotherapy of Prostate Cancer Using  $^{90}\text{Y}$  and  $^{177}\text{Lu}$  Labeled J591 Monoclonal Antibodies: Effect of Dose Fractionation and Multiple Treatments on Myelotoxicity. *Clin Cancer*, 2005; **11**:7195s-7200s.
103. Ross JS, Gray KE, Webb I, Gray GS, Rolfe M, Schenkein DP, Nanus DM, Milowsky MI, **Bander NH**: Antibody-Based Therapeutics: Focus on Prostate Cancer. *Cancer & Metast Rev*, 2005; **24**: 517-533.
104. **Bander, N.H.**: Technology insights: monoclonal antibody imaging of prostate cancer. *Nat Clin Pract Urol*, 2006;**3**(4):216-225.
105. David KA, Milowsky MI, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Nanus DM, **Bander NH**: Clinical Utility of Radiolabeled Antibodies in Prostate Cancer. *Clin Genitourin Cancer*, 2006; **4**(4):249-256.
106. Christiansen JJ, Weimbs T, **Bander N** and Rajasekaran AK: Differing effects of microtubule depolymerizing and stabilizing chemotherapeutic agents on t-SNARE-mediated apical targeting of prostate-specific membrane antigen. *Mol Cancer Ther*, 2006; **5**(10):2468-2473.
107. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Ross JS, and **Bander NH**: Vascular Targeted Therapy with Anti-PSMA Monoclonal Antibody J591 in Patients with Advanced Solid Tumor Malignancies. *J Clin Onc*, 2007; **25**:540-547.
- 108 Goodman OB, Barwe SP, Ritter B, McPherson P, Vasko A-J, Keen JH, Nanus DM, **Bander NH**, and Rajasekaran AK: Interaction of prostate specific membrane antigen with clathrin and adaptor protein complex-2. *Intl J Oncology*, 2007; **31**:1199-1203.
109. Wang AZ<sup>†a,c</sup>, Bagalkot V<sup>†b</sup>, Vasilliou C<sup>c</sup>, Gu F<sup>d</sup>, Alexis F<sup>a,d</sup>, Zhang L<sup>d</sup>, Shaikh M<sup>d</sup>, Yuet K<sup>d</sup>, Cima M<sup>c</sup>, Langer R<sup>d</sup>, Kantoff PW<sup>e</sup>, **Bander NH**<sup>f</sup>, Jon S<sup>\*b</sup>, Farokhzad OC<sup>\*a</sup>: Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy. *Submitted. (ChemMedChem)*
110. Philip H. Gutin, M.D., Mark A. Edgar, M.D., Peggy Moy, He Liu, MD, Pamela Salerno, P.A., **Neil H. Bander, M.D.**: Prostate-Specific Membrane Antigen for Vascular Targeting of Glioblastoma Multiforme. *Submitted*

#### **BOOK CHAPTERS:**

1. **Bander NH** and Cordon-Cardo C: Monoclonal antibody defined markers of human renal cancer. *In: Monoclonal Antibodies to Tumor Markers*, Sell S, Reisfeld R, (eds). Humana Press, Clifton, NJ, 1985.
2. Rosenberg S, **Bander NH** and Herr H: Testis tumors. *In: Current Therapy in Endocrinology*, Krieger D, Bardin W, (eds). BC Decker, Philadelphia, PA 1985.
3. **Bander NH**: Monoclonal antibodies. *In: American Urological Association Update*, Ball TP Jr, Novick DE, (eds). AUA Office of Education, Houston, TX 1986.
4. **Bander NH**: Monoclonal antibodies and the diagnosis and treatment of bladder cancer. *In: Bladder Cancer: Future Directions for Treatment*, Yagoda A, (ed). John Wiley & Sons, NY, NY 1986.
5. **Bander NH** and Klotz LH: Tumor immunology: *In: Urologic Oncology*, Graham S Jr, (ed). Raven Press, NY, NY 1986.
6. Klotz LH and **Bander NH**: Monoclonal antibodies and urologic oncology: Antigenic expression on genitourinary tumors. *In: Genitourinary Cancer*, Ratliff TL, Catalona WJ, (eds). Martinus Nijhoff Publishers, Boston, MA, 1987.
7. **Bander NH**: (ed). Renal cell carcinoma. *In: Seminars in Urology*, vol 7, no3, WB Saunders, Philadelphia, PA, 1989.
8. Ebert T and **Bander NH**: Immunodiagnosis of renal cancer. *In: Immunodiagnosis of Cancer*, Mercer DW, Herberman RB, (eds). Marcel Dekker, New York, NY 1990
9. Sheinfeld J, Cordon-Cardo C and **Bander NH**: Immunodiagnosis of bladder cancer. *In: Immunodiagnosis of Cancer*, Mercer DW, Herberman RB, (eds). Marcel Dekker, New York, NY 1990.
10. **Bander NH**, Gastl G, Nanus DM, Pfeffer LM, Finstad CL and Albino AP: Anti-proliferative and anti-tumor effect of  $\alpha$ -interferon in renal cell carcinoma: Correlation with the expression of a kidney associated differentiation glycoprotein. *In: Basic and Clinical Research on Renal Cell Carcinoma*, Staehler G, Pomer S, (eds). Springer-Verlag, Heidelberg, Germany 1992.
11. Gastl G, **Bander NH**, Frick J, Huber C and Aulitzky W: Immunotherapie des metastasierten nierenzellkarzinomas mit rekombinantem interferon-gamma. *In: Immunotherapie in der Uroonkologie*, Rubben H, Goepel M, Schmitz-Drager B, (eds). Springer-Verlag, Heidelberg, Germany 1993.
12. **Bander NH**: Current status of monoclonal antibodies for imaging and therapy of prostate cancer. *In: Seminars in Oncology*, Scher H., (ed). WB Saunders, New York, NY 1994.

13. Berger MF, Oosterwijk E, **Bander NH**, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, van Fleuren G, Oettgen HF and Old LJ: Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. *In: Biology of Renal Cell Carcinoma*, Bukowski RM, Finke JH, Klein EA, (eds). Springer-Verlag, New York, NY 1995.
14. **Bander NH**: Immunology of renal cancer. *In: Comprehensive Textbook of Genitourinary Oncology*, Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, (eds). Williams & Wilkins, Philadelphia, PA 1995.
15. Shemtov MM and **Bander NH**: Immunologic approaches to genitourinary malignancies. *In Campbell's Urology Update* (Patrick C Walsh, Alan B Retik, Thomas A Stamey, E Darracott Vaughan and Alan J Wein, (eds) Philadelphia, PA., 1996.
16. Ebert T, Anastasiadis A, **Bander NH**: Renal Cell Cancer in *Human Cell Culture* JR.W. Masters and B. Palsson (eds). Kluwer Academic Publishers 1999.
17. **Bander NH**: Monoclonal antibodies for imaging and therapy of prostate cancer. Klein E (ed). *Management of Prostate Cancer. Humana Press, Totowa, NJ: 1999.*
18. **Bander NH**: Monoclonal antibodies in the diagnosis and treatment of renal cancer. Vogelzang NJ et al (eds). *Comprehensive Textbook of Genitourinary Oncology, Second Edition, Lippincott Williams & Wilkins, Philadelphia, PA, 1999.*
19. Oosterwijk E, Divgi CR, Steffens MS and **Bander NH**: Monoclonal antibodies in advanced renal cell carcinoma. Bukowski RM and Novick AC (eds). *Renal Cell Carcinoma – Molecular Biology, Immunology, and Clinical Management, Humana Press, Totowa, NJ: 2000.*
20. Goldsmith SJ, **Bander NH**: Prostate cancer: Monoclonal Antibody Therapy. Khalkhali I, Maublant JC, Goldsmith SJ (eds). *Nuclear Oncology: Diagnosis and Therapy. Lippincott Williams & Wilkins, Philadelphia, 2001.*
21. Divgi CR, Oosterwijk E, **Bander NH**, Welt S, Larson SM, Old L: Renal Carcinoma: Monoclonal Antibody Therapy. Khalkhali I, Maublant JC, Goldsmith SJ (eds). *Nuclear Oncology: Diagnosis and Therapy. Lippincott Williams & Wilkins, Philadelphia, 2001.*
22. **Bander NH**: Editorial “Novel Therapy for PSA Progression in Absence of Imagable Disease Following Local Therapy. Cummings, K., (ed). *Management of Prostate Cancer: Advances and Controversies. Marcel Dekker, Inc, New York, NY: 2005.*
23. Ross JS, Gray, KE, Webb I, Gray GS, Rolfe M, Schenkein DP, Nanus DM, Milowsky MI, **Bander NH**: PSMA and Other Cell Surface Protein Targets For Antibody-Based Immunotherapy for Prostate Cancer, Ross J (ed). *Molecular Oncology of Prostate Cancer. Jones & Bartlett, Boston, MA., 2006.*

1.

**Date: January 27, 2009**

**Signature: *Neil H Bander***

